Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.52 |
| ▸ | CA2 | P00918 | 17/20 | 0.52 |
| ▸ | CA4 | P22748 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170624 | 0.88 | CA1 (0.53) | CA1CA2CA4CA12CA9 | |
| SCHEMBL6047697 | 0.88 | CA1 (0.64) | CA1CA2CA4CA12CA9 | |
| SCHEMBL6047706 | 0.83 | CA1 (0.49) | CA1CA2CA4CA12CA9 | |
| SCHEMBL15499792 | 0.79 | CA1 (0.75) | CA1CA2CA4CA12CA9 | |
| SCHEMBL17149908 | 0.79 | ALDH1A1 (0.45) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13523700 | 0.78 | CA1 (0.66) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13523716 | 0.78 | CA1 (0.59) | CA1CA2CA4CA12CA9 | |
| SCHEMBL17147596 | 0.77 | ALDH1A1 (0.47) | CA1CA2CA4CA12CA9 | |
| SCHEMBL12191709 | 0.76 | TDP1 (0.60) | CA1CA2CA4CA12CA9 | |
| SCHEMBL8913177 | 0.76 | TDP1 (0.60) | CA1CA2CA4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074387-B2 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20030202943-A1 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6565830-B1 | Contrast agent for imaging | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6287538-B1 | CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-5859214-A | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AKTIENGESELLSHAFT (DE) | 1999-01-12 | — | — | US | disclosed |
| US-5843399-A | DTPA monoamides for MRI | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| EP-0450742-B1 | DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AG (DE) | 1994-07-06 | — | — | EP | disclosed |
| EP-0450742-A1 | DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030202943-A1 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SLC43A1, HRH4, ACSL6 | CA1 84/4885CA2 13/4885CA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.